N. Ribelles

发表

Improvement of breast cancer relapse prediction in high risk intervals using artificial neural networks

J. M. Jerez, A. Lluch, A. Llombart-Cussac, 2005, Breast Cancer Research and Treatment.

A microRNA Signature Associated with Early Recurrence in Breast Cancer

J. M. Jerez, M. Claros, E. Alba, 2014, PloS one.

Predicting response and survival in chemotherapy-treated triple-negative breast cancer

E Mardis, E. Mardis, C. Fan, 2014, British Journal of Cancer.

Optimal adjuvant hormonal therapy in postmenopausal women with hormone-receptor-positive early breast cancer: have we answered the question?

E. Alba, N. Ribelles, Alfonso Sánchez-Muñz, 2010, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.

A. Ruíz, A. Lluch, S. González, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression.

E. Alba, N. Ribelles, P. Sánchez‐Rovira, 2008, Current drug metabolism.

Electronic health records and patient registries in medical oncology departments in Spain

N. Ribelles, C. Jara, J. Chacón, 2021, Clinical and Translational Oncology.

Insidious mastalgia hiding a desmoid tumour of the breast

N. Ribelles, B. Pajares, I. Galera, 2010, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.

F. Marmé, J. Pérez-García, A. Prat, 2021, The Lancet. Oncology.

Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer

N. Ribelles, J. García-Saenz, M. Gil-Gil, 2020, Clinical and Translational Oncology.

High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer

F. Rojo, J. Albanell, A. Ruíz, 2016, The oncologist.

Role of germline variants in the metastasis of breast carcinomas

A. González-Neira, A. Lluch, E. Alba, 2022, Oncotarget.

Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors

E. Alba, N. Ribelles, I. Barragán, 2020, Cancers.

Cyclophosphamide and ifosfamide combination as neoadjuvant chemotherapy for locally advanced nonsmall‐cell lung cancer: A meta‐analytic review

J. Carles, R. Rosell, N. Ribelles, 1990, Journal of surgical oncology.

Adjuvant Taxanes in Breast Cancer: A Critical Re-appraisal

E. Alba, N. Ribelles, A. Sánchez‐Muñoz, 2011 .

Elevated serum levels of vascular endothelial growth factor are associated with tumor-associated macrophages in primary breast cancer.

E. Alba, N. Ribelles, L. Vicioso, 2006, American journal of clinical pathology.

Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study

F. Rojo, J. Montero, A. Pandiella, 2019, Breast Cancer Research and Treatment.

Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.

A. Ruíz, V. Guillem, N. Ribelles, 2007, The Lancet. Oncology.

Prognosis of Microinvasive Breast Carcinoma with Negative Axillary Nodes in Accordance with TNM Classification Criteria

E. Alba, N. Ribelles, B. Pajares, 2010, The breast journal.

Aromatase inhibitors as adjuvant therapy for breast cancer: overall survival versus disease-free survival as a primary end point in clinical practice.

E. Alba, N. Ribelles, E. Pérez-Ruiz, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study

A. Ruíz, M. Margelí, E. Alba, 2010, Breast Cancer Research and Treatment.

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

M. Lux, R. Greil, A. Schneeweiss, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Significant Decrease in Annual Cancer Diagnoses in Spain during the COVID-19 Pandemic: A Real-Data Study

E. Alba, N. Ribelles, M. Cobo, 2021, Cancers.

Targeted treatment approaches in refractory germ cell tumors.

E. Alba, N. Ribelles, L. Galvez-Carvajal, 2019, Critical reviews in oncology/hematology.

Biweekly vinorelbine and tegafur/uracil in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: GEICAM 2000–02 phase II study

M. Margelí, N. Ribelles, M. Ramos, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Elevated serum levels of vascular endothelial growth factor are associated with tumor-associated macrophages in primary breast cancer.

E. Alba, N. Ribelles, L. Vicioso, 2006, American journal of clinical pathology.

Proliferation Determined by ki67 Marker and pCR in Locally Advanced Breast Cancer Patients Treated with Neo‐adjuvant Chemotherapy

E. Alba, N. Ribelles, P. Sánchez‐Rovira, 2013, The breast journal.

Phase I study of mitonafide in 120 hour continuous infusion in non-small cell lung cancer

J. Carles, R. Rosell, A. Abad, 1992, Investigational New Drugs.

The seed and soil hypothesis revisited: current state of knowledge of inherited genes on prognosis in breast cancer.

E. Alba, N. Ribelles, B. Pajares, 2014, Cancer treatment reviews.

Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer

E. Alba, N. Ribelles, L. Perez-Rivas, 2010, BMC Cancer.

Response to paclitaxel in a radiotherapy-induced breast angiosarcoma

N. Ribelles, E. Pérez-Ruiz, A. Román, 2009, Acta oncologica.

Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.

D. Kerr, J. Pignon, A. González-Neira, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HR+)/HER2-negative advanced breast cancer patients.

L. Franco, J. M. Jerez, E. Alba, 2020, European journal of cancer.

Six cycles of ABVD in the treatment of stage I and II Hodgkin's lymphoma: a pilot study.

E. Alba, N. Ribelles, A. Rueda, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Secondary Prophylactic G-CSF (Filgrastim) Administration in Chemotherapy of Stage I and II Hodgkin's Lymphoma with ABVD

E. Alba, N. Ribelles, M. A. De Las Nieves, 2001, Leukemia & lymphoma.

Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole

J. Mayordomo, I. Tusquets, E. Alba, 2006, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Randomized trial for the control of acute vomiting in cisplatin-treated patients: high-dose metoclopramide with dexamethasone and lorazepam as adjuncts versus high-dose alizapride plus dexamethasone and lorazepam. Study of the incidence of delayed emesis.

J. Carles, R. Rosell, N. Ribelles, 1991, Oncology.

A phase II study of days 1 and 8 cisplatin and recombinant alpha‐2B interferon in advanced non‐small cell lung cancer

J. Carles, A. Ariza, R. Rosell, 1991, Cancer.

A randomized study of two vindesine plus cisplatin‐containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non‐small cell lung cancer

J. Carles, R. Rosell, N. Ribelles, 1990, Cancer.

A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study

J. Albanell, A. Lluch, B. Cirauqui, 2012, Breast Cancer Research and Treatment.

Advanced Online Survival Analysis Tool for Predictive Modelling in Clinical Data Science

Daniel Urda, José Luis Subirats, Emilio Alba, 2016, PloS one.

Adjuvant anthracycline therapy as a prognostic factor in metastatic breast cancer

E. Alba, N. Ribelles, A. Rueda, 2001, Breast Cancer Research and Treatment.

Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications

E. Alba, N. Ribelles, M. Álvarez, 2019, Front. Oncol..

A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse

C. Perou, M. Dowsett, J. Parker, 2016, Clinical Cancer Research.

Chemotherapy (CT) with or without carboplatin as neoadjuvant treatment in patients with basal-like breast cancer: GEICAM 2006-03-A multicenter, randomized phase II study.

J. Albanell, A. Lluch, B. Cirauqui, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Male Breast Cancer: Immunohistochemical Subtypes and Clinical Outcome Characterization

E. Alba, N. Ribelles, C. Ramírez-Tortosa, 2012, Oncology.

Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay

S. Ferree, C. Schaper, P. Nuciforo, 2015, Clinical Cancer Research.

Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations

E. Alba, N. Ribelles, J. Trigo, 2012, Clinical and Translational Oncology.

Cisplatin, 5-fluorouracil, and high-dose folinic acid in patients with advanced unresectable head and neck cancer.

E. Alba, N. Ribelles, A. Rueda, 1996, American journal of clinical oncology.

Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients.

J. Carles, R. Rosell, A. Abad, 1992, European journal of cancer.

Maintenance treatment in metastatic breast cancer

E. Alba, N. Ribelles, E. Pérez-Ruiz, 2008, Expert review of anticancer therapy.

Missing data imputation using statistical and machine learning methods in a real breast cancer problem

Leonardo Franco, José M. Jerez, Ignacio Molina, 2010, Artif. Intell. Medicine.

Sequential Doxorubicin and Docetaxel as First-Line Treatment in Metastatic Breast Cancer: A GEICAM-9801 Phase II Study

E. Alba, N. Ribelles, A. Antón, 2004, Breast Cancer Research and Treatment.

Phase II feasibility study of high dose epirubicin plus etoposide and cisplatin (HDEEC) regimen in small cell lung cancer

R. Rosell, A. Abad, N. Ribelles, 1992, Investigational New Drugs.

Prolongation of TTP by maintenance therapy with PLD in a multicenter phase III randomized trial following standard chemotherapy for MBC: GEICAM 2001-01 study

M. Margelí, E. Alba, N. Ribelles, 2007 .

Design and implementation of a standard care programme of therapeutic exercise and education for breast cancer survivors

A. Cuesta-Vargas, E. Alba, N. Ribelles, 2021, Supportive Care in Cancer.

Is it Possible to Increase pCR in the Neoadjuvant Treatment With a Dose-Dense/Sequential Combination?: Results From a Phase II Trial Combining Epirubicin and Cyclophosphamide Followed by Paclitaxel and Gemcitabine ± Trastuzumab in Stage II and III Breast Cancer Patients

N. Ribelles, E. Carrasco, P. Sánchez‐Rovira, 2010, American journal of clinical oncology.

Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index

J. M. Jerez, L. Franco, E. Alba, 2013, Breast Cancer Research.

Supervised discretization can discover risk groups in cancer survival analysis

Leonardo Franco, José M. Jerez, Emilio Alba, 2016, Comput. Methods Programs Biomed..

Sequential Combination of Methotrexate (MTX), 5‐Fluorouracil (FU), and High‐Dose Folinic Acid (FA) in Advanced Colorectal Cancer: Double Biochemical Modulation?

J. Carles, R. Rosell, A. Abad, 1991, American journal of clinical oncology.

Chemotherapy (CT) de-escalation using an FDG-PET/CT (F-PET) and pathological response-adapted strategy in HER2[+] early breast cancer (EBC): PHERGain Trial.

F. Marmé, A. Prat, A. Llombart-Cussac, 2020 .

Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data

J. M. Jerez, A. Prat, E. Alba, 2019, Front. Oncol..

Luminal androgen receptor role and pathological complete response rate to neoadjuvant chemotherapy in triple negative breast cancer

J. M. Jerez, J. Albanell, A. Prat, 2016 .

Targeted therapy of metastatic breast cancer

N. Ribelles, E. Pérez-Ruiz, I. García-Ríos, 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.

A. Lluch, S. González, R. Andrés, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)

T. Ramón Y Cajal, M. Margelí, N. Ribelles, 2023, Clinical and Translational Oncology.

Outcome of Small Invasive Breast Cancer with No Axillary Lymph Node Involvement

E. Alba, N. Ribelles, B. Pajares, 2011, The breast journal.

The quotient of number of nodes and tumour size (N/T) from primary breast cancer predicts the clinical course after diagnosis of distant relapse.

N. Ribelles, E. Aranda, R. Dueñas, 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Looking for the right drug for the right patient: A tale of old drugs and new pathways

E. Alba, N. Ribelles, 2005, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Factors associated with upper limb function in breast cancer survivors

A. Cuesta-Vargas, E. Alba, N. Ribelles, 2021, PM & R : the journal of injury, function, and rehabilitation.

5-fluorouracil, ifosfamide and mitomycin (FIM) combination for pancreatic-biliary tumors.

J. Carles, R. Rosell, A. Abad, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer.

E. Alba, N. Ribelles, Víctor Navarro-Pérez, 2015, Clinical breast cancer.

Prosigna (PAM50) to predict response to neoadjuvant chemotherapy (NAC) in HR+/HER2- early breast cancer (EBC) patients.

S. Ferree, N. Dowidar, C. Schaper, 2015 .

High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer.

F. Rojo, J. Albanell, A. Ruíz, 2016, The oncologist.

Explainable clinical coding with in-domain adapted transformers

F. J. Veredas, José M. Jerez, E. Alba, 2023, J. Biomed. Informatics.

Detection of Tumor Morphology Mentions in Clinical Reports in Spanish Using Transformers

Francisco J. Veredas, Nuria Ribelles, Emilio Alba, 2021, IWANN.

Transformers for Clinical Coding in Spanish

Francisco J. Veredas, Nuria Ribelles, Emilio Alba, 2021, IEEE Access.

Serum protein levels following surgery in breast cancer patients: a protein microarray approach.

L. Franco, J. M. Jerez, E. Alba, 2012, International journal of oncology.

Addressing critical issues in the development of an Oncology Information System

Daniel Urda, Leonardo Franco, José Luis Subirats, 2013, Int. J. Medical Informatics.

Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.

D. Kerr, J. Pignon, A. González-Neira, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay

S. Ferree, C. Schaper, P. Nuciforo, 2015, Clinical Cancer Research.

Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine‐Induced Hand‐Foot Syndrome

J. Benítez, R. Milne, A. González-Neira, 2020, Clinical pharmacology and therapeutics.

Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.

A. Ruíz, A. Lluch, S. González, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Structural validity and reliability of the Spanish Central Sensitization Inventory in breast cancer survivors

E. Alba, N. Ribelles, B. Pajares, 2021, Pain practice : the official journal of World Institute of Pain.

Validation of the Upper Limb Functional Index on Breast Cancer Survivor

A. Cuesta-Vargas, N. Ribelles, Jaime Martín-Martín, 2023, International journal of environmental research and public health.

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

S. Cosimo, A. Prat, A. Llombart-Cussac, 2024, The Lancet.